Tech Company Financing Transactions
VivoSense Funding Round
Debiopharm Diagnostics and Xontogeny invested in a $25 million Series A capital raise for VivoSense. This venture round was announced on 3/30/2022.
Transaction Overview
Company Name
Announced On
3/30/2022
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Debiopharm Diagnostics (Lead Investor)
Xontogeny (Lead Investor)
Proceeds Purpose
The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs)
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
27 Dorian
Newport Coast, CA 92657
USA
Newport Coast, CA 92657
USA
Phone
Website
Email Address
Overview
Developer of a healthcare analytics software designed to optimize data quality and results. The company's software specializes in wearable sensor physiological monitoring alternatives, enabling pharmaceutical companies and researchers to get data analyzed at a low cost for their clinical trials and research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dudley Tabakin
Chief Technical Officer
Doug McAllister
VP - Bus. Development
Patrick Hankey
VP - Sales
Thomas Leonard
Browse more venture capital transactions:
Prev: 3/30/2022: Swaypay venture capital transaction
Next: 3/30/2022: Dagger venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs